ADHD Malta has said that it is deeply concerned about "the ongoing crisis surrounding the unavailability of ADHD medication, particularly Methylphenidate and Atomoxetine."

"This shortage has left many individuals in Malta, (as estimated by UN figures, 8% of the population is affected by ADHD), without access to the treatment vital for their quality of life," it said.

It spoke of the repeated exclusion of ADHD medications from the United Nations' List of Essential Medicines, "despite the significant impact ADHD has on millions worldwide. This decision has de-prioritised ADHD treatment globally, leading manufacturers to neglect production and distribution of these medications, particularly to smaller markets like Malta."

"Outdated evaluations citing 'poor research quality' on ADHD treatments, further exacerbate the issue. These dismissals ignore the voices of patients, who are experts by lived experience and rely on these medications daily. Patients' experiences must drive decisions on healthcare priorities," the group said.

ADHD Malta said that it appreciates the efforts of local authorities to find sources of medication, but emphasises that these efforts are not enough, "as medication is often unavailable".

"European manufacturers must urgently increase production and ensure equitable distribution of ADHD medications, especially to smaller nations like Malta. Patients across Europe deserve consistent access to their medication as a basic component of their health and well-being. While this is not a life-or-death issue, the inability to access treatment jeopardises the quality of life, employment, education, and relationships of individuals with ADHD."

ADHD Malta called for the following actions: "1. European manufacturers to increase prioritisation of the production of ADHD medication and establish reliable distribution channels to smaller countries. 2. Global health organisations and decision-makers to recognise the importance of ADHD medications, consulting patients and experts to update outdated and inaccurate evaluations. 3. Governments across Europe to collaborate and pressurise manufacturers to deliver on their obligations to supply medications to all markets."

"The exclusion of ADHD medications from the UN List of Essential Medicines cannot continue to dictate the access and availability of treatment. It is time for manufacturers, policymakers, and health organisations to prioritise patient needs. Regular access to ADHD medication is not optional - it is vital. ADHD Malta will continue to advocate for individuals with ADHD until this crisis is resolved," it said.